Avidity Biosciences Inc’s filing revealed that its Chief Scientific Officer Flanagan W. Michael unloaded Company’s shares for reported $0.78 million on Sep 11 ’25. In the deal valued at $38.94 per share,20,000 shares were sold. As a result of this transaction, Flanagan W. Michael now holds 80,195 shares worth roughly $3.32 million.
Then, WILLIAM MICHAEL FLANAGAN bought 20,000 shares, generating $928,000 in total proceeds.
Before that, WILSON TROY EDWARD sold 29,500 shares. Avidity Biosciences Inc shares valued at $1,475,000 were divested by the Director at a price of $50.00 per share. As a result of the transaction, WILSON TROY EDWARD now holds 54,425 shares, worth roughly $2.26 million.
A number of analysts have revised their coverage, including Bernstein’s analysts, who began to cover the stock in late June with a ‘”an Outperform”‘ rating. Wolfe Research began covering RNA with “an Outperform” recommendation on June 17, 2025. Raymond James started covering the stock on June 11, 2025. It rated RNA as “a Strong buy”.
Price Performance Review of RNA
On Tuesday, Avidity Biosciences Inc [NASDAQ:RNA] saw its stock jump 3.03% to $41.44. Over the last five days, the stock has lost -11.11%. Avidity Biosciences Inc shares have risen nearly 0.31% since the year began. Nevertheless, the stocks have risen 42.50% over the past one year.
How much short interest is there in Avidity Biosciences Inc?
A steep rise in short interest was recorded in Avidity Biosciences Inc stocks on 2025-08-29, growing by 1.36 million shares to a total of 17.57 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 16.21 million shares. There was a rise of 7.74%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 13, 2025 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $70 price target.
